Knowledge of risk factors for drug-resistant TB can help to analyse the likelihood of primary drug-resistant TB and facilitate the prescription of an adequate chemotherapy regimen. The most important risk factor, exposure to a drug-resistant TB patient, is already reflected in the clinical guidelines. However, we thought that the age and sex of a patient can also have a significant impact on the incidence of drug-resistant TB. Purpose: to study the age and gender characteristics of tuberculosis with primary drug resistance of Mycobacterium tuberculosis on the general population. Methods: 23,877 new TB cases reported in 2020 and 2021 were studied with evidence of Mycobacterium tuberculosis drug susceptibility to rifampicin, isoniazid, eiambutol, and fluoroquinolones. Results. The highest resistance to rifampicin, isoniazid and ethambutol is observed in patients aged 30-39 years. Rifampicin resistance in patients aged 30-39 years was 40.0%; 95% CI 38.9-41.1, to isoniazid - 49.4%; 95% CI 48.2-50.5, to ethambutol - 27.6%; 95% CI 26.6-28.6. It changes slightly in younger patients, but significantly decreases in patients of older age groups. In persons aged 50-59 and 60-69 years, resistance to rifampicin does not change significantly (30.4% and 28.6%, respectively; p>0.05). A similar "plateau" for isoniazid and ethambutol corresponds to the age groups of 70-79 and 80-89 years (for isoniazid - 28.4 and 27.0, respectively; p> 0.05; for ethambutol - 4.1% and 3.6% , respectively; p>0.05). The maximum resistance to fluoroquinolones is observed at the age of 0-9 years (13.6%; 95% CI 4.7-33.3) and 10-19 years (9.6%; 95% CI 7.0-13.0 ), however, its differences between neighboring age groups are statistically insignificant, with the exception of a decrease from the group of 30-39 years old (8.8%; 95% CI 8.2-9.5) to the group of 40-49 years old (7.1%; 95% CI 6.5-7.8). Rifampicin resistance in men was 35.2%, in women - 35.9%; p=0.3; to isoniazid: in men 45.7%, in women - 45.3%; p=0.6; to ethambutol: in men 35.4%, in women - 35.3%; p=1.0; to fluoroquinolones in men 7.0%, in women - 8.6%; p